MedTrace Logo

Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer

NCT03649945 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2018-08-28

No results posted yet for this study

Summary

This is an open-label, randomized trial, it compares the efficacy and safety between apatinib combined chemotheray and chemotherapy for adjuvant treatment of esophageal cancer

Conditions

  • Esophageal Cancer

Interventions

DRUG

Docetaxel

75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles

DRUG

Nedaplatin

80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles

DRUG

Endostar

7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles

Sponsors & Collaborators

  • First Affiliated Hospital of Guangxi Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2020-11-30
Completion
2021-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649945 on ClinicalTrials.gov